NASDAQ:CTNM Contineum Therapeutics Q3 2026 Earnings Report $12.92 -0.50 (-3.74%) As of 02:44 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Contineum Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.45Beat/MissN/AOne Year Ago EPSN/AContineum Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$5.65 millionBeat/MissN/AYoY Revenue GrowthN/AContineum Therapeutics Announcement DetailsQuarterQ3 2026Date10/29/2026TimeBefore Market OpensConference Call DateFriday, October 30, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Contineum Therapeutics Earnings HeadlinesContineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from JonesTradingSeptember 29 at 9:15 AM | theglobeandmail.comJ&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?September 24, 2026 | insidermonkey.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 1 at 1:00 AM | Banyan Hill Publishing (Ad)RBC Capital Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)September 23, 2026 | theglobeandmail.comContineum Therapeutics Inc. - Ordinary Shares - Class ASeptember 22, 2026 | money.usnews.comAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)September 22, 2026 | theglobeandmail.comSee More Contineum Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Contineum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Contineum Therapeutics and other key companies, straight to your email. Email Address About Contineum TherapeuticsContineum Therapeutics (NASDAQ:CTNM), formerly known as Pipeline Therapeutics, is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for diseases of the central nervous system. The company’s research is aimed at promoting remyelination and neurorepair, processes that may restore damaged nerve function rather than solely managing disease symptoms. Contineum’s lead programs include PIPE-307, an oral, brain-penetrant therapy designed to promote remyelination through selective inhibition of the M1 muscarinic receptor, and PIPE-791, an oral antagonist of the lysophosphatidic acid receptor 1. These candidates are being studied for potential applications in multiple sclerosis and other neurological or inflammatory diseases. The company was established as Pipeline Therapeutics and adopted the Contineum Therapeutics name in 2024. Based in San Diego, California, Contineum conducts research and clinical development activities through a biotechnology platform focused on central nervous system disorders, with its programs intended for patients in markets where regulatory approval may ultimately be obtained.View Contineum Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
